Replies to post #176504 on Biotech Values

[oc631]

[IDIX] If anyone here listened to the CC (or plans to listen), please post your CC notes.

I think everything IDIX says should be taken with a grain of salt (and a shot of Tequila). What disturbs me is the company is pursuing a European strategy for their follow-up nucleotide analog IDX-459. If the company had an exciting, safe compound they would immediately file an IND within the U.S. Hinting at future discussions with the FDA is a non-starter within this highly competitive space. Additionally, talk of a dual nuke combination is disingenuous since the company hasn't yet proven they can develop a safe Uridine analog.


The real news outside of IDIX's short notice, Monday morning C.C. was the resignation of the NVS backed director Anthony Rosenberg. NVS failing to appoint another director to the board is a clear no confidence vote for IDIX and suggests NVS is no longer interested in the company. I suspect there was a time NVS would have paid a large premium to acquire IDIX. It looks as if those days are gone for good.